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(H1N109) Strain of Influenza Virus in Hematopoietic
Stem Cell Transplant Recipients
Biju George,1 Patricia Ferguson,2 Ian Kerridge,1 Nicole Gilroy,2 David Gottlieb,1
Mark Hertzberg1There are limited data on the impact of H1N109 infection in patients undergoing hematopoietic stem cell
transplantation (HSCT). We reviewed individual medical records of patients who underwent HSCT or
were on follow-up post-HSCT between May and September 2009. Thirteen patients with H1N109 infection
were identified: 2\100 days post-HSCT, 7.100 days post-HSCT, and 4 just prior to HSCT. Five (38.7%) had
lower respiratory tract involvement (LRTI), whereas the remainder had upper respiratory tract involvement
(URTI). LRTI occurred in patients who were profoundly neutropenic post-HSCTor on potent immunosup-
pression for chronic graft-versus-host disease (cGVHD). At 100 days post-H1N109 infection, only 1 patient
with LRTI survived, whereas all with URTI are alive. Four patients successfully treated for H1N109 infection
prior to HSCTunderwent the procedure after 4 to 6 weeks without any complications. Another 6 patients
received oseltamivir prophylaxis during conditioning and none developed H1N109 infection. In conclusion,
H1N109 infection was associated with LRTI in HSCTrecipients who were profoundly neutropenic or immu-
nosuppressed. Prior H1N109 infection did not affect the successful outcome of HSCTand oseltamivir prophy-
laxis in a small group of recipients resulted in no infection. Further studies are required.
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The first case of H1N109 infection in Australia
was reported in May 2009, and the first wave of this
pandemic lasted in Australia until the end of Septem-
ber 2009. The reported rate of hospitalization was 23
per 100,000 population, with 13% of all patients who
were hospitalized being admitted to intensive care
units. The Australian pandemic was characterized by
the high number of patients who required ventilatory
support and the young age of confirmed cases of pan-
demicH1N109 infection who required hospitalization
(median age of 42 years) [1].1Department of Haematology; and 2Department of Infec-
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6/j.bbmt.2010.07.004Initial data from both Australia and the United
States identified underlying medical conditions such
as diabetes, obesity, chronic heart disease, and pulmo-
nary disease as risk factors for infection with H1N1
[2,3]. The U.S. data, in addition, identified that 15%
of patients were immunosuppressed either from
medication or immune disorders including human
immunodeficiency virus infection [3]. Patients under-
going hematopoietic stem cell transplant (HSCT) are
at a particular risk for community acquired respiratory
infections, and these contribute significantly to mor-
bidity and mortality in this high-risk group [4-6].
There is very limited data available on the impact of
infection with the H1N109 infection in this strikingly
vulnerable population [7]. Hence, in the setting of the
H1N109 pandemic, it was important to study whether
infection with the H1N109 strain of influenza was
associated with a worse outcome. This article describes
the experience with H1N109 infection among HSCT
recipients at a tertiary transplant center in Australia.PATIENTS AND METHODS
This is a retrospective analysis of all adult HSCT
patients undergoing treatment at Westmead Hospital,147
148 Biol Blood Marrow Transplant 17:147-153, 2011B. George et al.Sydney, betweenMay and September 2009, who devel-
oped infection with H1N109 influenza virus. The data
were collected from the hospital transplant database
and individual medical records. During the period
from May 1 to September 30, 2009, 31 transplants
were performed at our center, including 18 allogeneic
(14 reduced intensity conditioning (RIC) and 4myeloa-
blative) and 13 autologous transplants. In addition, 235
patients who had previously undergone HSCT were
seen in routine posttransplant follow-up.
Diagnosis of H1N109 Infection
Patients were diagnosed to have either upper respi-
tory tract infection (URTI) or lower respiratory tract in-
fection (LRTI) based on standard CDC criteria [8].
URTI was defined as the presence of nasal congestion
and/or rhinorrhea in the absence of lower tract symp-
toms, with a clear or unchanged chest radiograph.
LRTI or possible pneumonia was defined as the pres-
enceof the following characteristics: clinical findings, in-
cluding hypoxia, wheezing, and crackles at physical
examination; or evidence on a chest radiograph of new
pulmonary infiltrates. All patients reporting symptoms
had paired nose/throat swabs done for viral culture and
indirect immunofluorescence (IF) usingmonoclonal an-
tibodies against Influenza A andB, Parainfluenza viruses
type 1-3, respiratory syncytial virus, and adenovirus
(Chemicon Inc, Temecula, CA,USA). Viral polymerase
chain reaction (PCR) analysis was performed on all
patients with suspected H1N109 infection regardless
of the results of the antigen detection test [9]. Patients
reporting lower respiratory tract symptoms or signs
also had a chest radiograph. Patients who were febrile
and admitted to hospital had blood cultures taken. IF
andviral cultureswerealsoperformedonbroncoalveolar
lavage (BAL) specimens in patients whowere ventilated.
Prevention and Treatment of H1N109 Infection
All transplant patients were nursed in HEPA-
filtered rooms.Hand-washing protocols were followed
strictly by health care workers (HCWs) and relatives.
All visitors and HCWs entering the ward were
screened and anyone reporting respiratory symptoms
was prevented from entering the ward until complete
resolution of symptoms.
Transplant patients with respiratory symptoms
were transferred to respiratory isolation rooms con-
taining negative pressure ventilation. In addition, all
visitors and HCWs attending these patients needed
to use full-sleeved examination gowns, N 95 face
masks, and gloves. Upon diagnosis of H1N109 infec-
tion, all patients were treated with oseltamivir (Tami-
flu) at the dose of 75 mg twice a day orally for 5 days.
Paired nose/throat swabs were repeated after comple-
tion of treatment only in patients who continued
to be symptomatic. Even after treatment, patientscontinued to remain in respiratory isolation for the en-
tire period of their hospital admission.
Statistical Analysis
The day 100mortality was calculated from the date
of diagnosis of infection with H1N1 to date of last
follow-up or death. Differences between variables
were calculated using a paired Student’s t-test. Survival
was calculated using a KM analysis curve.RESULTS
Patients
BetweenMay and September 2009, 13 patients de-
veloped infectionwith theH1N109 virus. The baseline
characteristics of these patients are described in
Table 1.This included 9males and 4 femaleswith ame-
dian age of 53 years (range: 37-63 years). The majority
(76.9%) had an RIC transplant using anHLA identical
sibling donor. Nine patients (69.2%) had previous vac-
cination with the influenza vaccine in the past 12
months. Comorbidities identified included diabetes
mellitus and smoking in 3 patients each. For the pur-
pose of analysis, all patients were divided into 3 groups:
group 1 consisted of patients who developed infection
with swine flu early post HSCT (\100 days post-
HSCT) (n5 2); group 2 consisted of patients who de-
veloped infection with swine flu late post-HSCT
(.100 days post-HSCT) (n5 7); and group 3 consisted
of patientswhodeveloped infectionwith swine fluprior
to planned HSCT and then subsequently underwent
the transplant procedure (n 5 4).
Diagnosis of H1N109 Infection
All 13 patients presented with fever and sore throat,
with the majority having cough (Table 2). Five patients
(38.4%) also reported dyspnea and chest pain together
with signs suggestive of LRTI. The median age of pa-
tients with LRTIwas 61 years (range: 56-63 years) com-
pared to 47 years (range: 37-53 years) among patients
with URTI. All 5 patients with LRTI had abnormal
chest radiology ranging from unilateral to bilateral
patchy consolidation with collapse. Only 8 of the 13 pa-
tients (61.5%) were positive by antigen testing, whereas
all patients (100%) were positive by PCR for the
H1N109 strain. Five patients (60%) also had concomi-
tant bacterial infection at the time ofH1N109 infection.
This included Gram-negative sepsis with Pseudomonas
aeruginosa in 3 and Escherichia coli and Staphylococcus au-
reus in 1 patient each.
Clinical Course of Patients
Group 1 (early [\100 days] post-HSCT)
Between May and September 2009, 31 transplants
were performed at our center including 18 allogeneic
Table 1. Baseline Characteristics of HSCT Recipients
Developing H1N109 Infection
Variables Number (%)
Median age (years) 53.6 (37-63)
Sex
Male 9 (69.2%)
Female 4 (30.8%)
Diagnosis
Acute myelogenous leukemia/Myelodysplastic syndrome 7 (53.8%)
Low grade lymphoma/Chronic lymphatic leukemia 3 (23.1%)
Acute lymphoblastic leukemia 1 (7.7%)
Myelofibrosis 1 (7.7%)
Multiple myeloma 1 (7.7%)
Type of transplant
Myeloablative (MA) transplant 2 (15.4%)
Reduced intensity conditioning (RIC) transplant 10 (76.9%)
Autologous stem cell transplant (high-dose melphalan) 1 (7.7%)
Donors
HLA identical sibling 8 (61.5%)
Matched unrelated donors 3 (23.1%)
Haploidentical donors 1 (7.7%)
Autologus 1 (7.7%)
Comorbid medical conditions
Diabetes mellitus 3 (23.1%)
Smoking 3 (23.1%)
Chronic graft-versus-host disease (evaluable in 7)
Extensive 3 (42.8%)
Limited 4 (57.2%)
Number (%) who have previously received influenza vaccine 9 (69.2%)
HSCT indicates hematopoietic stem cell transplantation.
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oped swine flu in the immediate posttransplant period.
One patient, aged 61 years, undergoing an RIC trans-
plant for therapy-related myelodysplastic syndrome
(MDS) was diagnosed on day12 post-HSCTwhile be-
ing investigated for fever, cough, and breathlessness.
The diagnosis was made on nose/throat swab and was
also positive on a bronchoalveolar lavage. Because of in-
creasing respiratory distress, he required transfer to the
intensive care unit (ICU) for ventilatory support butwas
successfully extubated after 12 days and subsequently
discharged to the ward. He was treated with oral oselta-
mivir for 5 days but continued to remain positive
for H1N109 on BAL for another 2 weeks followingTable 2. Diagnosis of H1N109 Infection
Group 1 (<100 days) (n 5 2)
Median time from HSCT 7 days (2-16)
Symptoms
Fever 100%
Cough 100%
Sore throat 100%
Dyspnoea 100%
Lower respiratory tract involvement 100%
Coinfection with bacterial pathogens Pseudomonas aeruginosa and
Escherichia coli in 1 patient each
Admission in hospital 100%
Admission into ICU 100%
Diagnosis of H1N109
Antigen positive 100%
PCR positive 100%
HSCT indicates hematopoietic stem cell transplantation; ICU, intensive care u
*Because infection with H1N109 occurred pre-HSCT, this denotes median timcessation of treatment. He subsequently developed
acute graft-versus-host disease (aGVHD) and cytomeg-
alovirus (CMV) reactivation and required 2 further
admissions to the ICU before succumbing to nosoco-
mial pneumonia onday166 post-HSCT. Interestingly,
repeat paired nose/throat swabs done during the last ep-
isode of pneumoniawerenegative byPCR forH1N109,
and serum analysis showed evidence of the presence of
complement fixing antibodies against H1N109 (1:32
on day 30 after diagnosis of H1N1, 1:512 on day 46,
and 1:1024 on day 63).
The second patient, aged 63 years, underwent an
RIC transplant for acute myelogenous leukemia
(AML) in CR2 and was diagnosed with H1N109 on
day 116 post-HSCT. She was neutropenic and expe-
rienced massive gastrointestinal hemorrhage related
to severe ulcerative mucositis. She was initially started
on oral oseltamivir but was changed to inhalational
zanamivir in view of the concomitant severe gastroin-
testinal hemorrhage. She required invasive ventilatory
support for a period of 15 days, and following recovery,
was successfully extubated and discharged to the ward.
She remained quite debilitated following the ICU
admission and subsequently had repeated episodes of
infection, finally succumbing to nosocomial pneumo-
nia on day 93 post-HSCT. Repeat paired nose/throat
swabs were negative by PCR for H1N109.
Group 2 (Late [.100 days] post-HSCT)
Among 235 post-HSCT follow-up patients, 7 de-
veloped H1N1 infection, that is, an overall incidence
of 2.9%. Four patients (57.2%) had only upper respira-
tory tract symptoms, whereas 3 (42.8%) with LRTI
required hospital admission. A major determinant of
LRTI was the intensity of immunosuppression. All 3
patients with LRTI had extensive chronic GVHD
(cGVHD) and were on 2 to 3 immunosuppressive
drugs including steroids at.0.25mg/kg/day. Theme-
dian absolute lymphocyte count (ALC) for patients
with LRTI was 0.3  109/L (range: 0-0.7) comparedGroup 2 (>100 days) (n 5 7) Group 3 (Pre-HSCT) (n 5 4)
37 months (5-51) 42 days* (27-50)
100% 100%
85.7% 75%
100% 100%
42.8% 0
42.8% 0
Pseudomonas aeruginosa in 2
Staphylococcus aureus in 1
Nil
42.8% 0
28.5% 0
71.4% 25%
100% 100%
nit; PCR, polymerase chain reaction.
e to HSCT from diagnosis of H1N109 infection.
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patients without LRTI. The median CD4 count of pa-
tients with LRTI was 172/mL (range: 0-360) compared
to a CD4 count of 805/mL (range: 109-1064) among
patients with no LRTI (P\.001). All 4 patients with
upper respiratory symptoms were treated with oselta-
mivir for 5 days with complete resolution of symptoms.
Of the 3 patients with LRTI, 2 required transfer to the
ICU for ventilatory support for a median of 15 days.
Both patients who required admission to the ICU
died because of associated bacterial sepsis and multior-
gan failure. Five patients (71.4%) are alive and well and
have completely recovered from the infection.
Group 3 (Infection pre-HSCT)
Four patients, planned for HSCT, developed in-
fection with the H1N109 virus prior to HSCT. All 4
patients were treated on an out-patient basis with
oral oseltamivir for 5 days. All had subsequent paired
nose/throat swabs done at a median of 28 days (range:
25-32) after treatment with oseltamivir and all were
negative by PCR. After a median period of 42 days
(range: 27-50), all underwent HSCT (1 autologous
and 3 RIC allogeneic). None of the 4 patients received
oseltamivir prophylaxis during HSCT. None of the
patients had any complications related to H1N109
infection in the immediate posttransplant period. All
4 patients are alive and well .100 days post-HSCT.
Institution of Oseltamivir Prophylaxis
After initial episodes of infection with H1N109 in
the few HSCT recipients, all patients had paired nose/
throat swabs collected at admission. Patients about to
undergo RIC allogeneic transplantation who were
H1N109 negative received oseltamivir prophylaxis
75 mg once daily for a period of 10 days.
A total of 6 patients received oseltamivir prophy-
laxis between August and September 2009. None of
the patients developed infection with H1N109 in the
first 100 days post-HSCT. There was no significant
drug interaction noted with the use of oseltamivir as
a prophylactic agent.DISCUSSION
This retrospective analysis was aimed at exploring
the clinical impact of infection with the H1N109 virus
among HSCT recipients who are potentially at a high
risk because of severe immunosuppression. Because
there was no previously published literature on the
management of infectionwithH1N109 in immunosup-
pressed patients, establishment of treatment protocols
during the 2009 pandemic was dependent solely
on institutional experience with the management of
HSCT recipients with seasonal influenza virus infec-
tion. In our series, the median age of patients whodeveloped infection with the H1N109 virus was 53
years, with older patients tending to develop more
severe disease with LRTI. This differs from Australian
data available from the 2009 pandemic where H1N109
infection rates were highest among persons\25 years
of age, and death rates highest among persons aged 25
to 49 years. One potential explanation for this differ-
encemight be that a proportion of older individuals, es-
pecially those born before 1950, may have preexisting
crossreactive antibodies offering some protective im-
munity against the H1N109 virus [10,11]. The older
age group in our series is also a reflection of the age of
patients who undergo HSCT. In addition, infection
with H1N109 in post-HSCT recipients was seen pre-
dominantly with RIC transplants (77.7%). This was
true both among patients who were\100 days post-
HSCT and .100 days post-HSCT. This pattern is
different from published data on community-acquired
respiratory virus infections in HSCT recipients, which
suggests that although persons undergoing RIC trans-
plant have similar overall rates of acquisition of the virus
to those receivingmyeloablative conditioning, the inci-
dence of LRTIwas lower in the first 100 days [4]. LRTI
was seen primarily in patients who weremost immuno-
suppressed, either because they were profoundly neu-
tropenic and lymphopenic (immediately following
HSCT) or because they were receiving high doses
of immunosuppressive agents for the treatment of
cGVHD. The intensity of immunosuppression was
reflected in the significantly lower ALC and CD4
counts amongpatientswithLRTI compared to patients
without LRTI (Table 3). In addition, patients with
LRTI tended to be older, and this has previously been
described as 1 of the risk factors for respiratory viral in-
fections progressing into pneumonia [12].
All the patients with onlyURTI could be treated on
an out-patient basis and recovered completely from
their infection. This is similar to data that exists on
the management of influenza A infection in allogeneic
HSCT recipients .100 days posttransplant where all
respond to treatment with oseltamivir and do not
show progression to LRTI [13]. In contrast, all 5 pa-
tients with LRTI required hospitalization, with a ma-
jority requiring admission to the ICU for ventilatory
support. Although 3 of the 5 patients (60%) recovered
from the infection, 2 more eventually expired during
the same hospital admission because of unrelated
causes (Figure 1). The high mortality present among
patients with LRTI is similar to that reported with
the influenza virus where the case fatality rate among
HSCT recipients is 23% [14]. This is also consistent
with case reports of swineflu fromother transplant cen-
ters, 1 of which reported mortality in a patient with
LRTI, whereas the second patient with URTI recov-
ered with oseltamivir therapy [15]. However, in an
analysis of 21 HSCT recipients who developed
H1N1 infection in a U.S. center, only 8% had LRTI,
Table 3. Transplant Characteristics and Outcome of all HSCT Patients Who Had Infection with H1N109
S. No Age/Sex Diagnosis
HSCT
Type/
Donor
Day Post-HSCT/
CD4 count
Post-HSCT
Complication
LRT
Involved
Diagnosis on
Antigen PCR Course of Disease Outcome Present Status
1 61/M MDS RIC
MSD
2/0 Neutropenia Yes Pos Pos ICU admission; ventilated
for 12 days
Discharged from ICU Expired day 64 post-H1N109 e
bacterial pneumonia
2 63/F AML RIC
MSD
14/0 Neutropenia Yes Pos Pos ICU admission
ventilated for 15 days
Discharged from ICU Expired day 93 post-H1N109 e
bacterial pneumonia
3 56/M MF RIC
MSD
144/126 GVHD treated with
ATG/ Etanercept
Yes Pos Pos ICU admission
ventilated for 14 days
Expired in ICU Expired day 18 post-H1N109 e
ARDS + bacterial sepsis
4 50/M ALL MA
MSD
1520/1064 cGVHD not on treatment Nil Pos Pos Treated as out-patient Well Alive day 184 after H1N109
5 45/F AML RIC
MSD
425/109 cGVHD not on treatment Nil Pos Pos Treated as out-patient Well Alive day 171 after H1N109
6 61/M AML RIC
MUD
457/360 cGVHD on CSA +
Pred >0.25mg/kg
Yes Neg Pos Ward Admission Well Alive day 171 after H1N109
7 53/M NHL RIC
Haplo
393/460 cGVHD on Tac + Pred
>0.25mg/kg
Nil Neg Pos Treated as out-patient Well Alive day 171 after H1N109
8 37/M AML MA
MSD
1305/559 cGVHD on CSA + Pred
<0.25 mg/kg
Nil Pos Pos Treated as out-patient Well Alive day 171 after H1N109
9 61/M AML RIC
MUD
1541/31 cGVHD on CSA + Pred
>0.25 mg/kg
Yes Pos Pos ICU admission
ventilated for 7 days
Expired in ICU Expired day 11 post-H1N109 e
ARDS + bacterial sepsis
10 51/M Myeloma Auto Pre-HSCT NA Nil Neg Pos Treated as out-patient Well Had autoSCT 27 days after
H1N109
11 59/F AML RIC
MSD
Pre-HSCT NA Nil Neg Pos Treated as out-patient Well Had RIC AlloSCT 36 days after
H1N109
12 47/F CLL RIC
MSD
Pre-HSCT NA Nil Pos Pos Treated as out-patient Well Had RIC AlloSCT 50 days after
H1N109
13 53/M NHL RIC
MUD
Pre-HSCT NA Nil Neg Pos Treated as out-patient Well Had RIC AlloSCT 55 days after
H1N109
HSCT indicates hematopoietic stem cell transplant; RIC, reduced-intensity conditioning; MA, myeloablative; MSD, matched sibling donor; MUD, matched unrelated donor; cGVHD, chronic graft-versus-host disease;
CsA, cyclosporine; Tac, tacrolimus; Pred, prednisolone; LRT, lower respiratory tract; ICU, intensive care unit; ATG, antithymocyte globulin; NA, not applicable.
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Figure 1. OS of HSCTrecipients having lower respiratory tract involv-
ment (LRTI) versus upper respiratory tract involvement (URTI) with
H1N109.
152 Biol Blood Marrow Transplant 17:147-153, 2011B. George et al.with none requiring mechanical ventilation and no
deaths attributable to influenza [16]. In another report,
2 HSCT recipients with predominantly URTI
responded favorably to oseltamivir [17]. As is the case
with other respiratory viral infections, it is noteworthy
that the majority of the patients with LRTI also had
concomitant bacterial infection with either Gram-
positive or Gram-negative organisms that likely con-
tributed to morbidity and mortality.
The dismal outcome seen in patients with LRTI
despite treatment with oseltamivir probably indicates
that this high-risk group needs to be treated differently
from patients with isolated URTI alone. Some authors
have suggested an initial treatment for 10 days, with
a more prolonged course being reserved for patients
with pneumonia and for those with continuing symp-
toms or ongoing evidence of viral shedding [7]. Pro-
spective studies are required to determine the optimal
duration of therapy in this group of patients. Likewise,
it is essential that specific preventive strategies need to
be identified for 2 distinct high-risk groups: those who
are profoundly neutropenic and immunosuppressed
following HSCT, and those with active extensive
cGVHD who are profoundly immunosuppressed as
a consequence of receiving multiple immunosuppres-
sive drugs. In our series, about 70% of cases had previ-
ously been immunized against influenza during the past
12 months, suggesting that there is no crossprotection
offered by the standard flu vaccine, and hence, one
probably needs to consider vaccination with the new
swine flu vaccine prior to HSCT for both the recipient
as well as family members. Vaccination of the donor
may also be an additionalmeasure to consider. A recent
meta-analysis on hand hygiene suggested that frequent
use of hand-hygiene measures is associated with a 55%reduction in the risk of acquiring respiratory virus in-
fections [18]. In addition to practicing strict preventive
measures, we used oseltamivir prophylaxis (75mg once
daily for 10 days) in a small group of patients (n 5 6)
partly based upon a previous study of strategies to
prevent influenza A infection in HSCT recipients and
on other studies of preemptive therapy with neuramin-
idase inhibitors (ie, oseltamivir, zanamivir) which dem-
onstrated efficacy in preventing progression to lower
tract disease [19,20]. None of these 6 developed
infection with H1N109 post-HSCT and none experi-
enced clinical, pharmacologic, or laboratory adverse
events as a consequence of oseltamivir prophylaxis.
Hence, it may be reasonable to consider the use of
oseltamivir prophylaxis for HSCT recipients during
outbreaks of H1N109 virus. However, prospective
studies will need to be conducted to establish the utility
of prophylaxis and identify whether the use of prophy-
laxis will lead to an increase in oseltamivir resistant
strains of this virus.
In our experience, previous infection withH1N109
prior to HSCT did not seem to have an adverse impact
on the outcomeof the transplant, as 4 patients (3 alloge-
neic and1 autologousHSCT)proceeded successfully to
HSCT about 4 to 6 weeks after treatment for H1N109
infection. It is noteworthy that these 4 patients had only
URTI such that it is difficult for us to draw any conclu-
sions as towhether previous LRTIwithH1N109 infec-
tion would have resulted in an adverse outcome
following subsequent HSCT.
Based upon this limited experience in treating
HSCT recipients with H1N1 infection, we believe
that the highest risk of mortality are in patients who
are either in their early transplant period (\100 days)
or those with cGVHD on intense immunosuppression
(as reflected in low CD4 counts). All HSCT recipients
with symptoms suggestive of influenza should have
paired nasopharyngeal swabs taken and started on ther-
apeutic doses of oseltamivir for 5 days. Prophylaxis can
be considered 2 categories: (1) patients undergoing
HSCT during conditioning and until neutrophil
engraftment, and (2) patients with cGVHD with low
CD4 counts.
In conclusion, infection with theH1N109 strain of
the influenza virus was associated with LRTI and
a poor outcome among HSCT recipients, especially
those with profound neutropenia and those with
cGVHD on intense immunosuppressive therapy.
Prior infection with the H1N109 virus did not have
an impact prospectively on patients having HSCT at
a later date. Oseltamivir prophylaxis was employed in
a few patients with no drug interaction and no evidence
of infection with the H1N109 virus. Prophylactic and
preventive strategies need to be studied in HSCT
recipients who are at a high risk of developing LRTI.
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